Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide
Objective
Chronic obstructive pulmonary disease (COPD) is a global disease characterised by chronic obstruction of lung airflow interfering with normal breathing. Although the microbiota of respiratory tract is established to be associated with COPD, the causality of gut microbiota in COPD development is not yet established. We aimed to address the connection between gut microbiota composition and lung COPD development, and characterise bacteria and their derived active components for COPD amelioration.
Design
A murine cigarette smoking (CS)-based model of COPD and strategies evaluating causal effects of microbiota were performed. Gut microbiota structure was analysed, followed by isolation of target bacterium. Single cell RNA sequencing, together with sera metabolomics analyses were performed to identify host responsive molecules. Bacteria derived active component was isolated, followed by functional assays.
Results
Gut microbiota composition significantly affects CS-induced COPD development, and faecal microbiota transplantation restores COPD pathogenesis. A commensal bacterium Parabacteroides goldsteinii was isolated and shown to ameliorate COPD. Reduction of intestinal inflammation and enhancement of cellular mitochondrial and ribosomal activities in colon, systematic restoration of aberrant host amino acids metabolism in sera, and inhibition of lung inflammations act as the important COPD ameliorative mechanisms. Besides, the lipopolysaccharide derived from P. goldsteinii is anti-inflammatory, and significantly ameliorates COPD by acting as an antagonist of toll-like receptor 4 signalling pathway.
Conclusion
The gut microbiota–lung COPD axis was connected. A potentially benefial bacterial strain and its functional component may be developed and used as alternative agents for COPD prevention or treatment.
Top-30
Journals
|
2
4
6
8
10
12
|
|
|
International Journal of COPD
12 publications, 4.84%
|
|
|
Frontiers in Microbiology
11 publications, 4.44%
|
|
|
Frontiers in Cellular and Infection Microbiology
7 publications, 2.82%
|
|
|
Nutrients
6 publications, 2.42%
|
|
|
Frontiers in Immunology
6 publications, 2.42%
|
|
|
International Journal of Molecular Sciences
6 publications, 2.42%
|
|
|
Gut Microbes
6 publications, 2.42%
|
|
|
Frontiers in Pharmacology
4 publications, 1.61%
|
|
|
Frontiers in Medicine
4 publications, 1.61%
|
|
|
Journal of Ethnopharmacology
4 publications, 1.61%
|
|
|
Medicine (United States)
4 publications, 1.61%
|
|
|
International Journal of Biological Macromolecules
4 publications, 1.61%
|
|
|
Respiratory Research
3 publications, 1.21%
|
|
|
Heliyon
3 publications, 1.21%
|
|
|
Journal of Agricultural and Food Chemistry
3 publications, 1.21%
|
|
|
Food Bioscience
3 publications, 1.21%
|
|
|
Scientific Reports
3 publications, 1.21%
|
|
|
Probiotics and Antimicrobial Proteins
2 publications, 0.81%
|
|
|
Microorganisms
2 publications, 0.81%
|
|
|
Frontiers in Nutrition
2 publications, 0.81%
|
|
|
Journal of Translational Medicine
2 publications, 0.81%
|
|
|
AMB Express
2 publications, 0.81%
|
|
|
Lung
2 publications, 0.81%
|
|
|
Food Science and Human Wellness
2 publications, 0.81%
|
|
|
Microbial Pathogenesis
2 publications, 0.81%
|
|
|
Biomedicine and Pharmacotherapy
2 publications, 0.81%
|
|
|
iMeta
2 publications, 0.81%
|
|
|
Food and Function
2 publications, 0.81%
|
|
|
COPD: Journal of Chronic Obstructive Pulmonary Disease
2 publications, 0.81%
|
|
|
2
4
6
8
10
12
|
Publishers
|
5
10
15
20
25
30
35
40
45
|
|
|
Springer Nature
43 publications, 17.34%
|
|
|
Elsevier
42 publications, 16.94%
|
|
|
Frontiers Media S.A.
39 publications, 15.73%
|
|
|
MDPI
28 publications, 11.29%
|
|
|
Taylor & Francis
22 publications, 8.87%
|
|
|
Wiley
21 publications, 8.47%
|
|
|
Cold Spring Harbor Laboratory
8 publications, 3.23%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
7 publications, 2.82%
|
|
|
American Society for Microbiology
4 publications, 1.61%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 1.21%
|
|
|
American Chemical Society (ACS)
3 publications, 1.21%
|
|
|
Tsinghua University Press
2 publications, 0.81%
|
|
|
BMJ
2 publications, 0.81%
|
|
|
American Physiological Society
2 publications, 0.81%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.4%
|
|
|
SAGE
1 publication, 0.4%
|
|
|
American Thoracic Society
1 publication, 0.4%
|
|
|
Institute of Electrical and Electronics Engineers (IEEE)
1 publication, 0.4%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.4%
|
|
|
Research Square Platform LLC
1 publication, 0.4%
|
|
|
Impact Journals
1 publication, 0.4%
|
|
|
Korean Society for Microbiology and Biotechnology
1 publication, 0.4%
|
|
|
Oxford University Press
1 publication, 0.4%
|
|
|
Hans Publishers
1 publication, 0.4%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 0.4%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.4%
|
|
|
The Royal Society
1 publication, 0.4%
|
|
|
Mary Ann Liebert
1 publication, 0.4%
|
|
|
Spandidos Publications
1 publication, 0.4%
|
|
|
5
10
15
20
25
30
35
40
45
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.